atezolizumab
roche,medsir
['sclc', 'atezo', 'nsclc', 'atezo-brain', 'medsir']
updated analysis from atezo-brain by : atezolizumab+carboplatin+pemetrexed yields 30.5% 2-year os rate in untreated brainmets from nsclc pts, regardless of treatment w/ corticosteroids @ baseline &amp; pd-l1 expression
40% confirmed intracranial orr (12 pr, 4 cr)
#asco22 
Bring your idea to life?? 
Creating successful IITs & optimizing drug development ?? 
Medica Scientia Innovation Research
 ????&????
https://t.co/yp3O5Lylqc